Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NITE Nightstar Therapeutics (NITE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Nightstar Therapeutics Stock (NASDAQ:NITE) 30 days 90 days 365 days Advanced Chart Ad WealthPressThe indicator behind Nvidia’s rally has a new prospectEvery now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Nightstar Therapeutics alerts:Sign Up Key Stats Today's Range$29.53▼$29.8150-Day Range$25.41▼$25.4152-Week Range$9.59▼$29.55Volume7,235 shsAverage Volume185,808 shsMarket Capitalization$999.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.Read More… The indicator behind Nvidia’s rally has a new prospect (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Receive NITE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nightstar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NITE Stock News HeadlinesKnight Therapeutics: Strong Revenue Growth and Strategic Prospects Justify Buy RatingNovember 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Knight Therapeutics (OtherKHTRF) and OnKure Therapeutics (OKUR)November 9, 2024 | markets.businessinsider.comMedia Is Mocking Elon, But Wait Until They See This DemoElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.December 3, 2024 | Brownstone Research (Ad)Knight Therapeutics price target lowered to C$6.25 from C$6.75 at StifelNovember 9, 2024 | markets.businessinsider.comWindtree Therapeutics $WINT Announces Positive Phase 2b Results In Early Cardiogenic Shock TreatmentOctober 7, 2024 | msn.comNITE The Nightview ETFSeptember 25, 2024 | seekingalpha.comThank you for supporting The Big Night InNovember 12, 2023 | bbc.co.ukBills vs. Giants Sunday Night Football highlights: Buffalo survives for late winNovember 1, 2023 | usatoday.comSee More Headlines NITE Stock Analysis - Frequently Asked Questions How were Nightstar Therapeutics' earnings last quarter? Nightstar Therapeutics PLC (NASDAQ:NITE) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.13. When did Nightstar Therapeutics IPO? Nightstar Therapeutics (NITE) raised $76 million in an initial public offering on Thursday, September 28th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers. What other stocks do shareholders of Nightstar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nightstar Therapeutics investors own include Canopy Growth (CGC), Cronos Group (CRON), OncoMed Pharmaceuticals (OMED), Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals (LGND), Neurocrine Biosciences (NBIX) and Sangamo Therapeutics (SGMO). Company Calendar Last Earnings11/13/2018Today12/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:NITE CUSIPN/A CIK1711675 Webwww.nightstartx.com Phone44-20-7062-2777FaxN/AEmployees47Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.89% Return on Assets-27.65% Debt Debt-to-Equity RatioN/A Current Ratio8.54 Quick Ratio8.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.89 per share Price / Book5.06Miscellaneous Outstanding Shares33,540,000Free FloatN/AMarket Cap$999.65 million OptionableNot Optionable Beta2.84 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:NITE) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nightstar Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Nightstar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
